ClinicalTrials.gg
Enrolling by invitationNCT06997458LOLA-PROJECTUpdated May 30, 2025

Liquid BiOpsy, Lung and Colon Cancer in AndaluciA

An observational study in Non Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain — 160 open to participants now, 333 under way, 112 of them phase 3. Carcinoma, Non-Small-Cell Lung · Spain.

Planned enrollment
14th of 48
500 · median 216
Started
2024
with 66 others
Observational
48 of 851
12 open now
Primary completion
2025-07
later than 50 of 332 live
Registered
788th of 851
by date

Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, this one is the 14th largest by planned enrollment of the 48 observational ones that give a count, is one of 67 that started in 2024, is one of 48 observational ones, reaches primary completion later than 50 of the 332 other live ones, and was the 788th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

160 of the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, or all of them as a file.
02

Study summary

The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.

03

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)

Keywords

  • Liquid Biopsy
  • cfDNA
  • ctDNA
  • Metastatic Cancer
  • NGS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Metastatic adenocarcinoma (NSCLC: 250 and CRC: 250)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General criteria:

  • More than 18 years old
  • Both genders
  • Ability to provide written

Specific criteria:

  • NSCLC

    • Patients diagnosed with the 8th Edition of the Tumor, Node, (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
    • confirmed NSCLC (adenocarcinoma)
    • Performance status of 0-2 ( PS) ○ Estimated ≥3 months
    • Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
    • Smokers or Non-Smokers
  • CRC

    • Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
    • Histologically confirmed CRC (adenocarcinoma)
    • Performance status of 0-2 (ECOG PS)
    • Estimated life expectancy ≥3 months
    • Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).

Exclusion criteria

Exclusion Criteria:

  • General: History of any other cancer within the previous 5 years, except non-melanoma skin cancer
  • General: Absence of . > Pregnant or nursing women. > Small cell lung cancer.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with radiologic evidence of metastatic (stage IV) NSCLC

    * Patients diagnosed with the 8th Edition of the Tumor, Node, Metastasis (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c) * Histologically confirmed NSCLC (adenocarcinoma) * Performance status of 0-2 (ECOG PS) * Estimated life expectancy ≥3 months * Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy). * Smokers or Non-Smokers

    Diagnostic Test: xF Tempus assay

  • Patients with radiologic evidence of metastatic (stage IV) CRC

    * Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c). * Histologically confirmed CRC (adenocarcinoma). * Performance status of 0-2 (ECOG PS) * Estimated life expectancy ≥3 months * Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).

    Diagnostic Test: xF Tempus assay

Interventions

  • Diagnostic testxF Tempus assay

    The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs. The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021). The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021).

06

What researchers measure

Primary outcomes

  1. To analyse the impact of adopting large (TEMPUS) NGS panels in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost.

    Proportion of patients with at least one actionable variant (%)

    Time frame: through study completion, an average of 3 year

07

Study locations

1 site
  • Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO)
    Granada, Andalucia 18016, Spain
08

References and documents

Publications

  • Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, Malapelle U, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ; ISLB. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020 Jul;151:102978. doi: 10.1016/j.critrevonc.2020.102978. Epub 2020 May 5. PubMed 32428812 ↗
  • Rolfo C, Denninghoff V. Globalization of precision medicine programs in lung cancer: a health system challenge. Lancet Reg Health Eur. 2023 Dec 12;36:100819. doi: 10.1016/j.lanepe.2023.100819. eCollection 2024 Jan. No abstract available. PubMed 38170059 ↗
  • Pisapia P, Costa JL, Pepe F, Russo G, Gragnano G, Russo A, Iaccarino A, de Miguel-Perez D, Serrano MJ, Denninghoff V, Quagliata L, Rolfo C, Malapelle U. Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. Crit Rev Oncol Hematol. 2021 May;161:103311. doi: 10.1016/j.critrevonc.2021.103311. Epub 2021 Mar 26. PubMed 33781866 ↗
  • Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, Khan AA, Lozac'hmeur A, McKinnon KE, Perera J, Zhu W, Dowlati A, White KP, Tell R, Beaubier N. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021 Jul 2;5(1):63. doi: 10.1038/s41698-021-00202-2. PubMed 34215841 ↗
  • Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, De Miguel-Perez D, Denninghoff V, Duran I, Jantus-Lewintre E, Nuzzo PV, O'Byrne K, Pauwels P, Pickering EM, Raez LE, Russo A, Serrano MJ, Gandara DR, Troncone G, Rolfo C. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Rev Mol Diagn. 2021 Nov;21(11):1165-1178. doi: 10.1080/14737159.2021.1985468. Epub 2021 Oct 11. PubMed 34570988 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2025, 11 months after the start.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 11 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 30, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Jul 30, 2025
CompletionEst.
Jul 30, 2026
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06997458
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Collaborators
Tempus AI
Responsible party
María José Serrano Fernández (Principal Investigator, Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental) — Principal investigator
First posted
May 30, 2025
Start date
Aug 1, 2024
Primary completion
Jul 30, 2025 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
May 30, 2025

Study contacts

M Jose Serrano, PhD
principal investigator · Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO) & University Hospital Virgen de la Nieves
Valeria Denninghoff, PhD
study director · Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion